Naaman Tammuz

$105 million for the next frontier of Alzheimer’s treatment - and it’s not another monoclonal antibody. Cognito Therapeutics announced the close of an oversubscribed $105 million Series C, bringing its total funding to $233 million. The round was led by Morningside Ventures, IAG Capital Partners, and Starbloom Capital, with strong participation from new investors including New Vintage Partners, Apollo Health Ventures, and Benvolio Group. At the center of this momentum is Spectris, a physician-prescribed, at-home wearable neurostimulation device that looks like sleek sunglasses connected to over-ear headphones. Patients simply wear it for one hour per day while it delivers precisely synchronized 40 Hz gamma-frequency light and sound stimulation. By non-invasively restoring disrupted gamma brain rhythms that decline early in Alzheimer’s, the therapy drives meaningful downstream effects. It reduces amyloid and tau pathology, helps preserve brain structure such as the corpus callosum, and meaningfully slows neurodegeneration. In the completed OVERTURE Phase 2 randomized, sham-controlled study and its open-label extension, patients using Spectris experienced a 77 percent reduction in the decline of daily function on the ADCS-ADL scale, a 76 percent reduction in cognitive decline on the MMSE, a 69 percent reduction on the integrated Alzheimer’s Disease Rating Scale, and a 56 percent lower Alzheimer’s Dependence Score. These benefits were sustained through the 18-month open-label extension, all with excellent safety and no serious device-related adverse events. The device carries FDA Breakthrough Device Designation for cognitive and functional symptoms in Alzheimer’s. A non-pharmacological, disease-modifying therapy that patients can use comfortably at home, with the potential for fewer side effects and far broader accessibility than today’s anti-amyloid infusions. It also opens the door for future expansion into other neurodegenerative diseases. #AlzheimersDisease #Neurotechnology #Neurodegeneration #DigitalHealth #Biopharma #Neuroscience #BreakthroughDevice #Longevity